Antipsychotic drugs opposite to metabolic risk: Neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome

Open Neurology Journal

Volumn 7, Issue 1, 2013, Pages 23-31

  Milano, Walter ^a   De Rosa, Michele ^a   Milano, Luca ^a   Capasso, Anna ^b  

^a District 24 ASL Napoli 1 Center   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antipsychotic drugs; Metabolic risk; Weight gain

Indexed keywords

ADIPONECTIN; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CLOZAPINE; DOPAMINE; ESTROGEN; FATTY ACID; GESTAGEN; GHRELIN; HALOPERIDOL; HISTAMINE; INSULIN; LEPTIN; MOOD STABILIZER; NEUROHORMONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; OREXIN; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2C RECEPTOR; STEROID; UNINDEXED DRUG; ZIPRASIDONE;

ARTICLE; BODY MASS; CHEMICAL INTERACTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; DYSLIPIDEMIA; HEALTH; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 84879152620     PISSN: None     EISSN: 1874205X     Source Type: Journal    
DOI: 10.2174/1874205X01307010023     Document Type: Article

References (60)

1. Dickerson FB, Brown CH, Kreyenbulh JA. Obesity among individuals with serious mental llness. Acta Psychiatr Scand 2006; 113 (4): 306-13.
2. Ryan MC, Flanagan S, Kinsella U. Atypical antipsychotics and visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci 2008; 74:1999-2008.
3. Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Adv Psychiatr Treat 2005; 11:125-32.
4. WHO. Obesity: preventing and managing the global epidemic. 2000; WHO Technical Report Series, number 894, Geneva: WHO 2000
5. Haslam DW, James WPT. Obesity. Lancet 2005; 366:1197-209.
6. Kenchaiah S, Gaziano JM, Vasan RS. Impact of obesity on the risk of heart failure and survival after onset of heart failure. Med Clin North Am 2004; 88: 1273-94.
7. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
8. Herva A, Laitinen J, Miettunen J. Obesity and depression. Int J Obes 2006; 30:520-7.
9. Puhl RM, Henderson KE, Bronwell KD. Social consequences of obesity. In: Kopelman PG, Catergon ID, Dietz WH, Eds Clinical obesity. 2nd ed. Oxford: Blackwell Publishing 2005; pp. 29-45.
10. Reist C, Mintz J, Alberts L. Second-generation antipsychotic exposure and metabolic- related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol 2007; 27:46-51.
11. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2c receptor and antipsychotic induced weight gain: mechanism and genetics. J Psychopharmacol 2006; 20:15-8.
12. Deng C, Weston-Geeen C, Huang XF. The role histaminergic H1 and H3 receptors in food-intake: a mechanism for atypical antipsychotic- induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1-4.
13. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanism and management. Aust N Z J Psychiatry 2008; 42: 369-381.
14. Virk S, Schwartz TL, Jindal S. Psychiatric medication induced obesity: an aetiological review. Obes Rev 2004; 5:167-70.
15. McQuade RD, Stock E, Marcus R. A comparasion of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65:47-56.
16. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009; 11: 665-79.
17. Zinnerman U, Kraus T. Epidemiology, implications and mechanisms underlying drugs-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37:193-220.
18. Alvarez-Jimenez M, Gonzales-Blanch C, Crespo-Facorro B. Antipsychotic- induced weight gain in chronic and first-episode psychotic disorders. A systematic critical reappraisal. CNS Drugs 2008; 22 (7): 547-62.
19. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009; 10:527-42.
20. Han L, Deng C, Burne THJ. Short- and long- term effects of antipsychotics drugs treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 2008; 33: 569-80.
21. Reynolds GP, Kirk SL Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms Pharm Ther 2010; 125: 169-79.
22. Osborne DP, Levy G, Nazareth I. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Arch Gen Psychiatry 2007; 64 (2): 242-249.
23. Meier U, Gressner AM Endocrine regulation of energy metabolism: review of phatobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem 2004; 50 (9): 1511-25.
24. Ellingrod VL; Bishop JR, Moline J. Leptin and leptin receptor gene polimorphisms and increase in body masss index from olanzapina treatment in persons with schizophrenia. Psychopharmacol Bull 2007; 40:57-62.
25. Popovic V, Doknic M, Marie N. Change in neuroendocrine and metabolic hormones induced by atypical antipsychotic in normalweight patients with schizophrenia. Neuroendocrinol 2007; 85: 249-56.
26. Muraschita M, Kusumi I, Inoue T. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinol 2005; 30: 106-10.
27. Correll CU. Weight gain and metabolic effects of mood stabilazers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007; 46 (6): 687-700.
28. Saha S, Chant D, McGrant J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64 (10):1123-31.
29. Correll CU, Malhorta AK. Pharmachogenetic of antipsychoticinduced weight gain. Psychopharmacol 2004; 174 (4): 477-89.
30. Zhang ZJ, Yao ZJ, Liu W. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62.
31. Sentissi O, Epelbaum J, Oliè JP, Poirier MF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizphr Bull 2008; 34 (6): 1189-99.
32. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M. Pronounced, early increase in circulating leptin predicts lower weight gain during clozapine treatment. J Clin Psychopharmacol 2002; 22: 424-6.
33. Mulder H, Franke B., Van Der Beek AA. The association between HTR2c gene polymprphism and metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 238-343.
34. Mandelli V, Pariante C. Metabolic syndrome and obesity in psychosis: the possible mechanisms. Obes metab 2008; 4: 59-64.
35. Bozina N, Medved V, Kuzman MR. Association study of olanzapina- induced weight gain and therapeutic response with SERT gene polymorphism in female schizophrenic patients. J Psychopharmacol 2007; 21: 728-34.
36. Chagnon YC. Susceptility genes for the side effects of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7: 1681-1695.
37. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863-87.
38. Templeman LA, Reynold GP, Arranz B, San L. Polymorphism of 5-HT2c receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian sujet with a first-episode psychosis. Pharmachogenet Genomics 2005; 15 (4):195-200.
39. Tiwari AK, Zai CC, Likhodi O. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic- induced weight gain in schizophrenia. Neuropsychopharmacology 2010; 35 (6): 1315-24.
40. Liu YR, Loh EW, Lan TH. ADRA1A gene is associated with BMI in cronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010; 10 (1): 30-9.
41. Baptista T, Lacruz A, De Mendoza S. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81-8.
42. Milano W, D'Acunto CW, Capasso A. Recent clinical aspects of hyperprolactinaemia induced by antipsycgotics. Rev Recent Clin Trials 2011; 6 (1):1-13.
43. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
44. Alberti KG, Zimmer P, Shaw J. The IDF Epidemiology Task force Consensus Group. The Metabolic Syndrome: a new worldwide definition. Lancet 2005; 366:1059-62.
45. Hanson RL, Imperatore G, Bennet PH, Knowlwr W. Components of metabolic syndrome and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-7.
46. Pramyothin P, Khaodhiar L.Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obesity 2010; 17: 460-66.
47. De Hert M, Schreurs V, Vancampfort D. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8:15-22.
48. Meyer JM, Sthal SM. The metabolic syndrome and schizophrenia Acta Psychiatr Scand 2009; 119: 4-14.
49. Patel JK, Buckley PF, Woolson S. Metabolic profiles of secondgeneration antipsychotic in early psychosis: findings from the CATIE study. Schizophr Res 2009; 111: 9-16.
50. De Hert M, Hanssens L, Wampers M. Prevalence and incidence rates of metabolic abnormalities and diabetes in prospective study of patients treated with second-generation antipsychotics Schizphr Bull 2007; 33: 560-4.
51. Correl CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 (4):26-36.
52. Kumra S, Oberstar JV, Sikich L. Efficacy and tolerability of second- generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008; 34:60-71.
53. Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 2004; 19 (1): 1-93.
54. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic and endocrinological disorders. Psychiatr Clin N Am 2009; 32: 775-94.
55. Dandona P, Aljada A, Chaudhuri A. Metabolic Syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation. 2005; 111: 1448-54.
56. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother 2010; 10 (7): 1175-200.
57. American Diabetes Association; American Psychiatric Association; American Association of Clinical endocrinologists; North American Association for Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65(2): 267-72.
58. Leucht S, Corves C, Arbter D. Second-generation versus firstgeneration antipsychotic drug for schizophrenia: a meta-analysis. Lancet. 2009; 373 (9657): 31-41.
59. Lieberman JA, Stroup, McEvoj JP. Effectiveness of antipsychotic drugs on patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209-23.
60. McEvoj JP, Lieberman JA, Perkins DO. Efficacy and tolerability of olanzapina, quetiapine and risperidone in the treatment of early psychosis: a randomized, double-blind 52 weeck comparison. Am J Psychiatry 2007; 164: 1050-60.